CD274 and neoplasm: Despite the low-grade tumor PDXs behaving less aggressively—animals’ survival and tumor-doubling time overcame both variables for high-grade BCs in the appropriate control group—and had a similar PD-L1-expressing status, they did not respond to the therapy.